CA3179361A1 - Bacteriophage compositions for treating pseudomonas infection - Google Patents

Bacteriophage compositions for treating pseudomonas infection

Info

Publication number
CA3179361A1
CA3179361A1 CA3179361A CA3179361A CA3179361A1 CA 3179361 A1 CA3179361 A1 CA 3179361A1 CA 3179361 A CA3179361 A CA 3179361A CA 3179361 A CA3179361 A CA 3179361A CA 3179361 A1 CA3179361 A1 CA 3179361A1
Authority
CA
Canada
Prior art keywords
seq
bacteriophage
polynucleotide sequence
identity
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179361A
Other languages
English (en)
French (fr)
Inventor
Sebastien Lemire
Stacey Lynn KOLAR
Brian Clarke VARNUM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armata Pharmaceuticals Inc
Original Assignee
Armata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armata Pharmaceuticals Inc filed Critical Armata Pharmaceuticals Inc
Publication of CA3179361A1 publication Critical patent/CA3179361A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3179361A 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection Pending CA3179361A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016132P 2020-04-27 2020-04-27
US63/016,132 2020-04-27
PCT/US2021/029412 WO2021222257A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Publications (1)

Publication Number Publication Date
CA3179361A1 true CA3179361A1 (en) 2021-11-04

Family

ID=76284135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179361A Pending CA3179361A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Country Status (8)

Country Link
US (3) US12594312B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142760A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023523319A (cg-RX-API-DMAC7.html)
CN (1) CN116018154A (cg-RX-API-DMAC7.html)
AU (1) AU2021263735A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179361A1 (cg-RX-API-DMAC7.html)
IL (1) IL296741A (cg-RX-API-DMAC7.html)
WO (1) WO2021222257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
JP2023523319A (ja) * 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ
WO2025219447A1 (en) 2024-04-17 2025-10-23 Hun-Ren Biological Research Centre Szeged Region-specific phage compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962419B2 (en) * 2012-03-19 2018-05-08 Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
WO2018106135A2 (en) * 2016-12-05 2018-06-14 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
EP3584314A4 (en) * 2017-02-17 2020-09-16 Intron Biotechnology, Inc. NEW BACTERIOPHAGE OF PSEUDOMONAS AERUGINOSA (PSE-AEP-3) AND ITS USE TO INHIBIT THE PROLIFERATION OF PSEUDOMONAS AERUGINOSA
AU2019205241C1 (en) * 2018-01-02 2026-04-30 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infections
JP2023523319A (ja) * 2020-04-27 2023-06-02 アルマタ・ファーマシューティカルズ・インコーポレーテッド シュードモナス感染症を処置するためのバクテリオファージ組成物

Also Published As

Publication number Publication date
IL296741A (en) 2022-11-01
US20210330722A1 (en) 2021-10-28
JP2023523319A (ja) 2023-06-02
CN116018154A (zh) 2023-04-25
AU2021263735A1 (en) 2022-10-27
EP4142760A1 (en) 2023-03-08
US20230174954A1 (en) 2023-06-08
US20240226205A1 (en) 2024-07-11
WO2021222257A1 (en) 2021-11-04
US12594312B2 (en) 2026-04-07
CN116018154A9 (zh) 2023-10-24

Similar Documents

Publication Publication Date Title
US12594312B2 (en) Bacteriophage compositions for treating Pseudomonas infection
US12239677B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
US20250170195A1 (en) Bacteriophage compositions for treating pseudomonas infections
US11253557B2 (en) Therapeutic bacteriophage compositions
JP2023507080A (ja) 呼吸器抗菌性ファージを含むカクテル組成物及びその使用方法
US11717561B2 (en) Multimodal antimicrobial therapy
HK40092898A (en) Bacteriophage compositions for treating pseudomonas infection
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250411

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250411

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250411

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250414

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250526

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250526

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323